TLR7/8 antagonist 2
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC50s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases[1].
Product Specifications
CAS Number
[2769085-03-0]
UNSPSC
12352005
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tlr7-8-antagonist-2.html
Purity
99.68
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(C2=C(C=C3C(NN=C3N[C@H]4CCNC[C@@H]4F)=C2)C5CC5)=CC(C)=N1
Molecular Formula
C22H26FN5
Molecular Weight
379.47
References & Citations
[1]Claudia Betschart, et al. Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an In Vivo Efficacious TLR7/8 Antagonist.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Browse additional items from our catalog
NEUROD2 sgRNA CRISPR Lentivector (Human) (Target 1)
SARS-CoV-2 Spike S1 Protein (T19R & T95I & E156G & 157-158 deletion & L452R & T478K & D614G & P681R, His)
SARS-CoV-2 Spike S1 Protein (T19R & T95I & E156G & 157-158 deletion & L452R & T478K & D614G & P681R, His)
SARS-CoV-2 Spike S1 Protein (T19R & T95I & E156G & 157-158 deletion & L452R & T478K & D614G & P681R, His)